šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV Ā· Real-Time Price Ā· USD
38.73
+0.02 (0.05%)
At close: Nov 18, 2026, 4:00 PM EST
38.80
+0.07 (0.18%)
Pre-market: Nov 19, 2026, 4:00 AM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

LISRAYA generated $31 million in sales through Sept. 30, with consistent demand and a broad early prescriber base. Late-stage RA, Graves’, MG and PH-ILD programs advanced, with Graves’ and MG data expected in 2027.

Dennis Ding
Biotech Analyst, Jefferies

Hi, good afternoon. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, Biotech Analyst here at Jefferies. I have the wonderful pleasure of having Roivant CEO Matt Gline here. Welcome.

Matt Gline
CEO, Roivant Sciences

Thanks for having me. It's great to be here again.

Dennis Ding
Biotech Analyst, Jefferies

Maybe just to start off, just recap what has happened this year with Roivant. You guys have a lot of positive data and a lot of progress, so maybe just help set the stage there for us.

Matt Gline
CEO, Roivant Sciences

Yeah, thanks. It's been a quiet, uneventful 2026 for us. Not much to speak of.

Dennis Ding
Biotech Analyst, Jefferies

Very quiet.

Matt Gline
CEO, Roivant Sciences

No, look, it has been an amazing year in a way that makes you super appreciative and nervous about how you are going to follow it up. It is almost hard to figure what has happened this year. We started off the year, this time last year at this conference, we had relatively recently announced the positive DM data, and were sort of on a path to getting that drug registered. We were a couple weeks away from our first Investor Day, looking forward. Early in 2026, we put out really nice data in our phase II study in cutaneous sarcoidosis. That was sort of kicking off the year, adding a proper second pillar for Brepo from an indication perspective. We then went on to also announce LPP as a phase II/III program that is ongoing. We failed in TED.

We announced our period one positive D2T RA data that we have now finished that study, and the whole thing was successful, which is great. We then later this year, back in September, announced really good data from our PH-ILD program, mosliciguat, and we launched LISRAYA. We got approved in August. I think I have not missed anything. I think that is what happened this year.

Dennis Ding
Biotech Analyst, Jefferies

Yeah.

Matt Gline
CEO, Roivant Sciences

Just that.

Dennis Ding
Biotech Analyst, Jefferies

Well, there's obviously a lot of talk about

Matt Gline
CEO, Roivant Sciences

Oh, we also settled with Moderna.

Dennis Ding
Biotech Analyst, Jefferies

That's right.

Matt Gline
CEO, Roivant Sciences

That happened in March.

Dennis Ding
Biotech Analyst, Jefferies

That's right. That's right. A very positive settlement. Maybe we could just start off with LISRAYA, because I feel like that's what a lot of investors are focused on in the near term. You guys had $31 million in revenue in the last quarter. Maybe talk a little bit about demand and what you're hearing from doctors and just the overall excitement that both patients and doctors are seeing on the ground.

Matt Gline
CEO, Roivant Sciences

Yeah, perfect. Look, we're obviously, we've said this a bunch of times, it's early days, it's hard to know at this stage, but super pleased with how the first six weeks that we reported went. Demand is good. Patients are, as best we can tell, excited. Docs are excited. So it's been a great early dynamic, as you said. Through September 30, we had $31 million in sales. Fair amount of that was pharmacies buying drug in anticipation, but we've since dispensed all of it. So, a really nice first period and just good consistent demand through here. Feedback, I'd say, if anything, we had hundreds of patients on drug at the end of September. We had many hundreds of patients on paid drug in both cases, many of those patients on paid drug by November 9th.

We had many hundreds of prescribers, a good number of whom have only written one or two scripts, which is actually an awesome place to be at this stage of the launch. Because on the one hand, we have places like Johns Hopkins where we expect a lot of scripts. We've gotten a lot of scripts, a lot of enthusiasm from docs in some cases who were investigators on our study. But there's a long tail here of myositis centers and even some community rheumatology practices that are writing drug, where they're writing at this point what I would call test scripts. One or two patients have come through, it's a novel therapy, they're putting some patients on it, waiting to get feedback from those patients. And that's a great spot to be at this stage of the launch.

Those patients obviously haven't come back around yet, but they will later this year, early next year, into the first half of next year. As those patients cycle through, hopefully we'll be able to get a little bit of a positive feedback flywheel. So we feel really good about where we're at. Again, it's much too early to make any projection from here, and the payer dynamics are just starting to change in a way that we knew was going to happen. We're getting to see some real policies in place, and some are challenging, like the Centene policy that was announced even before we had the drug approved, that does require an IVIG step. But on the other hand, we have a Cigna- Express Scripts policy that only requires a step through a steroid and one immunosuppressant.

We have another policy from Caremark that has similarly good sort of step criteria. Overall, feeling pretty solid, as much as you can know at this stage.

Dennis Ding
Biotech Analyst, Jefferies

Okay. Maybe as it relates to the typical patient profile who are being prescribed LISRAYA, can you kind of give a little bit more color? Are they coming from JAKs? Are they coming from IVIG?

Matt Gline
CEO, Roivant Sciences

Yeah. What we predicted when we got into this is that there wasn't going to be a sort of specific profile, that it was going to be a pretty wide diversity of patients, and that's exactly what we've seen. There are some practices that use a lot of off-label JAKs, and a lot of those practices have moved a significant number of patients over. There are some practices that didn't use a lot of off-label JAKs to begin with, and some of those patients are IVIG heavy and are switching IVIG patients. But we also have a lot of patients who are just on ISTs or steroids and need a new option and didn't view themselves or their doc didn't view them as eligible for IVIG or for JAKs, and many of those patients have come.

We've had some newly diagnosed patients put on drugs, so we've seen a pretty broad range of patients at this point.

Dennis Ding
Biotech Analyst, Jefferies

Okay. Is it fair to assume that the vast majority of patients come from some of these tertiary centers, these academic centers, or would you say that it is a little bit broader?

Matt Gline
CEO, Roivant Sciences

It is a mixture. It is broader than I think vast majority is probably an overstatement, although there is a lot of parsing language going on here. But I think that a lot of patients come from these referral centers, but we also have a decent amount of prescribing from community rheums and derms at this point. And I would say there are at least a couple of high-prescribing practices that are community offices, some of whom we did not even know prior to the commercial launch. So, it has been a variety. It is certainly weighted towards the academic referral centers, but I think it is a broader. If there has been one surprise in the launch, it is that it is a broader base of early prescribers than I think I expected.

Dennis Ding
Biotech Analyst, Jefferies

Sure. Okay. How should we think about the quarter ending in December in terms of revenue? And we can talk about inventory, we can talk about quarter-over-quarter growth, because sometimes investors or analysts might get carried away and think $31 million in the first quarter, let us assume $60 million or $70 million for the next quarter. So, I am going to try to give you an opportunity to kind of put your message out there.

Matt Gline
CEO, Roivant Sciences

We thought about it carefully, and we decided we were not going to give guidance at the 10-Q, and instead we were going to save it and give guidance both for the quarter and the year ahead at this conference. So, no, I am not going to do that. But I made Kay nervous, though. Look, I think the main thing that we have said over and over and over again is it is just early. It is hard to know. We were happy with patient demand through the filing of the Q last week. We definitely had a tailwind from pharmacy ordering behavior in the quarter ending September 30. I think we will have a modest headwind from those same dynamics in the quarter ending December 31, and then I think inventory will wind up irrelevant thereafter, largely.

But there's still a pretty wide range of outcomes in terms of how this all plays out from a demand perspective, from a payer perspective, so it's hard to call explicitly. I think that's why you might hear a little bit of conservatism from us relative to what you might otherwise normally get by tripling 31.

Dennis Ding
Biotech Analyst, Jefferies

Okay. But you're not seeing a bolus early on?

Matt Gline
CEO, Roivant Sciences

I have learned in 2026 that that is not a word that pharma CEOs or biotech CEOs are permitted to utter, so I will not use it here. But, look, I think the first couple weeks we saw maybe a slightly higher level of prescribing demand, but since then, it's been fairly consistent. I think that still makes it impossible to tell whether we are in some early innings demand behavior, either to the low side or to the high side, relative to where we'll wind up.

Dennis Ding
Biotech Analyst, Jefferies

Yeah.

Matt Gline
CEO, Roivant Sciences

But so far, other than that, all I can say is it's been pretty consistent.

Dennis Ding
Biotech Analyst, Jefferies

Okay. So, it sounds to me like we're still in the early days, right? The demand looks pretty encouraging so far. Access and the breadth and the way that the product is being prescribed looks pretty encouraging.

Matt Gline
CEO, Roivant Sciences

Yeah, I agree with all of that. I think that's a fair characterization.

Dennis Ding
Biotech Analyst, Jefferies

Okay. Then, you guys had really good data in NIU, right? So, you guys are going to submit that—

Matt Gline
CEO, Roivant Sciences

Oh, right. I forgot that too when I was recapping the year. That's true.

Dennis Ding
Biotech Analyst, Jefferies

I guess, how should people think about the launch once you get approved later in 2027?

Matt Gline
CEO, Roivant Sciences

Yeah. We haven't given guidance on when we expect to get approved in NIU. Nice try, though. Look, I think we were really happy with that NIU data. Frankly, NIU patients are in a post-HUMIRA setting, out of options, basically, and it's one of the leading causes of blindness. There's a lot of unmet need. HUMIRA leaves a lot of room on the table, right? There's a significant proportion of patients, half of patients fail in clinical settings. If you look in the claims data, again, these patients are getting worse. They're going on higher dose steroids, they're getting local therapy, they're going blind at some rate. So, I think there's a ton of unmet need. As you may remember from the HUMIRA trial, half of the patients fail. The median time to treatment failure in the HUMIRA studies was under six months. In our study, it was unmeasurable.

That is more than the duration of the study. Patients had not failed by the time the study was over. So, just amazing clinical data that I think sets us up really well. I think in terms of error bars from a commercial market perspective, and I think the error bars from NIU certainly overlap fully with the error bars from DM. That is, NIU, given the number of patients, could be just as big an indication as dermatomyositis. There's a ton of patients. I think the HUMIRA dynamics are a little bit different, and so depending on how the label reads and how the insurance policies work, we may be initially, at least, in a HUMIRA refractory setting, but our data is certainly good enough that I expect to grow the pie overall. Just feeling really excited about that opportunity.

I think we're probably going to spend a reasonable amount of time at Investor Day talking about our enthusiasm for that commercial landscape, what it looks like from a prescriber perspective, why we're excited about it, because I think it's coming soon. I think it's pretty wild to think we're going to be launching a second indication relatively near future.

Dennis Ding
Biotech Analyst, Jefferies

Have you talked about pricing and how you are going to approach that for NIU, given its 45 mg?

Matt Gline
CEO, Roivant Sciences

We have not talked much about it. The truth of the matter is, we have only had the clinical data for a couple weeks. We are just beginning the proper payer conversations that you can have at this stage. Even more so, I think some of those conversations can not even really begin until you have a PDUFA date, which we obviously do not yet. I think it is early days. I think, what is the envelope of options? Anything is, in theory, possible. It is a different dose, a different tablet, so you could launch it under a different brand at any price you want. I think it is relatively likely that we will either price at parity, so the same price as 30 mg, or that we would price per milligram, and I think both of those options remain on the table.

Dennis Ding
Biotech Analyst, Jefferies

Sure. Okay. You guys announced LPP, and you guys are also in cutaneous sarcoid, but that is already a lot, right? You can already get to, in my view, $8 billion-$10 billion in peak sales from those indications alone. How much further can it go? How much of a priority is it for you guys to announce additional indications?

Matt Gline
CEO, Roivant Sciences

I think it is a huge priority to announce additional indications. I think there are We have a short list at some level of 10 more. There is a lot of places to go. I think we are excited to get it going in as many of those as we can. I think especially now that the NIU study is rolling off, we have capacity to start the additional next one or two or whatever it is, and I think we are hard at work, A, choosing that indication, and B, getting it going in the near future. I think Brepo is a drug that deserves to be approved in many indications.

Dennis Ding
Biotech Analyst, Jefferies

Do you think that is something that you guys would disclose more details at the Investor Day in December?

Matt Gline
CEO, Roivant Sciences

Probably not on indication expansion for Brepo specifically, because our general sort of mode on this stuff is mostly we like to wait until these studies are for some definition of up and running, like up and running by the time we announce them, for competitive reasons, for locking up, figuring out what sites we want to work with, stuff like that. So I think probably it is like a little premature, but hopefully soon.

Dennis Ding
Biotech Analyst, Jefferies

Okay. Let us shift gears a little bit to the FcRn space. So you guys had some unexpectedly positive period two data.

Matt Gline
CEO, Roivant Sciences

I agree.

Dennis Ding
Biotech Analyst, Jefferies

Maybe remind us of what that was, and then the next steps as it relates to the FDA.

Matt Gline
CEO, Roivant Sciences

Yeah, perfect. As a reminder, we are studying our anti-FcRn antibody, IMVT-1402, in this multi-mechanism failure late-line RA. These are RA patients who, in addition to failing steroids and immunosuppressants, have failed at least two biologics, whether that is a JAK inhibitor or an IL-6, a TNF. These are patients who have failed some of the most potent anti-inflammatories ever invented. On top of that, they had to be positive for autoantibody levels. I think going into early this year, this was a pretty high-risk program. Nipocalimab had some mixed data on RA in the patient populations they chose. It just was not 100% clear where we were going to land. Earlier this year, we put out our period one data. This was a randomized withdrawal study.

All patients were on high-dose drug for about 16 weeks, sorry, and then stepped into either staying on high dose, dropping down to 300 mg, or dropping down to placebo, on a randomized blinded basis. The goal of period one was to show robust responses in an open-label setting for 16 weeks, and then the goal of period two was that when you took those patients off for 12 weeks, you lost some of those responses on placebo. We showed exactly that. The period one data was incredibly strong. We showed about three-quarters of patients getting to an ACR20, a little bit more than half of patients getting to an ACR50, and about 35% of patients getting to an ACR70, where the highest placebo ACR70 observed is maybe in the teens, and most of them are single digits.

This was very good data, especially in this refractory setting. What we said at the time is that we were not frankly sure we were going to be able to hit a p-value in period two, just because the period two population is only the population that has hit an ACR20, and talking about a significant portion of those had been pretty deep responders, ACR50 and ACR70. Talking about losing an ACR20 response, it is a pretty high bar in 12 weeks for patients that have been pretty well managed on drug. It turns out, we saw a nice separation at the high dose. We saw about 25% of patients lost their response on placebo compared to about, whatever, 7% or 8% on drugs. A nice separation, a decent p-value. We also saw good separation and nominal p-value on ACR50 loss of response, et cetera.

An unexpectedly positive data set, as you put it, and something that I think sets us up really well for the ongoing FDA conversations that we're now having around the phase III design, as well as just conviction around what this program could be going forward. I think multi-mechanism failure RA is a great indication. There are a lot of patients there, patients who are in bad need. They are in a lot of pain. They often have mobility issues. They have failed many lines of therapies, which in part is disappointing in the sense they have tried, but it means they are willing to seek pharmacotherapy. They have tried lots of things. They are good candidate patients for us, and we think we have pretty well selected for these patients based on the nature of the failures and, frankly, the quality of the data.

Dennis Ding
Biotech Analyst, Jefferies

What are the different range of possibilities around the future phase III pivotal design in this program?

Matt Gline
CEO, Roivant Sciences

Yeah. I think there is really, any study has like a million little study design considerations. There are really four questions about the study. One is how many are there, because they are one study or two. One is how many patients. One is what is the endpoint? Is it ACR20, ACR50, et cetera? Then one is what is the duration of the study? I think those are the main open questions. The truth is, I am not sure we are that focused on economizing in the sense that I think it is a great patient population and it is important that it work. I think, one study versus two, even N, we are probably relatively open on.

I will say, I think we are hoping we do not have to dose thousands of patients, just given the nature of the population, and I would be a little surprised, but that is one set of parameters. On endpoint, I think you could imagine ACR20 has been the historical coin of the realm endpoint for RA. I think we might prefer a more stringent endpoint, like an ACR50 or an ACR70, just because it makes the powering calculus slightly easier. Then, I think on duration, in general, I think it is easier for us to separate on longer duration studies, but FDA has historically had quite a significant preference for shorter studies in RA, and so we will have to have that discussion with them and see where it shakes out.

Dennis Ding
Biotech Analyst, Jefferies

Do you think that the FDA appreciates that you guys are focused on a really late-line segment of the disease, and you also have to be, I believe, ACPA positive? What I am trying to get at is, do you think the FDA appreciate that this opportunity is not first-line RA, and that it is actually sort of an orphan indication?

Matt Gline
CEO, Roivant Sciences

I think FDA will unquestionably understand that we have chosen a different population than frontline. I think FDA is often concerned both about reaching the broadest possible set of patients as well as avoiding backdoor paths to larger patient populations, so I think the FDA will ask us a variety of questions around our chosen patient population just to get to the bottom of that. But I think ultimately, all of our experiences with the FDA and with the rheum division specifically suggest they are smart, thoughtful regulators who are going to want a new option for patients that need one. I think it should be a constructive dialogue, and I do think they will understand this population. Well, look, unfortunately, it failed, but there was a company called Artiva running an NK cell program in a similarly refractory patient population.

I think the FDA has clearly sort of understood and circumscribed late-line RA as a meaningful population of unmet need at some level.

Dennis Ding
Biotech Analyst, Jefferies

Okay. Well, you guys will also have Graves' data next year.

Matt Gline
CEO, Roivant Sciences

Yeah.

Dennis Ding
Biotech Analyst, Jefferies

Maybe just remind us, because that is a really, really important catalyst for you guys.

Matt Gline
CEO, Roivant Sciences

I mean, imitation is the finest form of flattery, and so now there's—

Dennis Ding
Biotech Analyst, Jefferies

There's a lot of people.

Matt Gline
CEO, Roivant Sciences

—a dozen companies running around in Graves' disease, which is awesome, honestly. Graves' is one of these therapeutic markets. There are literally millions of diagnosed Graves' patients, hundreds of thousands of them poorly controlled despite all the available therapeutic options. Many of them are told disheartening things like, well, the best we can do for you got to have your thyroid removed. So, it's just a huge opportunity, and it's awesome in the literal meaning of that word to see how much work is now going into treating Graves' patients, who just a couple of years ago were sort of literally off the map in terms of what biotech companies were doing. So I find that really exciting. It's a big patient population. The biological rationale for IgG autoantibody downregulation in Graves' disease is about as good as it gets, right?

This is a disease that is clearly caused in large part by pathogenic IgG autoantibodies to the thyroid, to the TSH receptor in particular. I think it will be interesting, like stimulatory antibodies, right? It will be interesting to see what happens. There is obviously always a little bit of risk that comes from being the first to study an indication. There are interesting trial design considerations. There is a lot of heterogeneity in how Graves' patients are treated in terms of use of antithyroid drugs. There are practices that treat with high-dose ATDs and manage thyroid hormone levels effectively, but leave patients uncomfortable with ATD side effects. There are practices that tend to manage with lower-dose ATDs and leave patients often somewhat hyperthyroid. There are just different approaches. But overall, like I said, I feel like this is a nice shot on goal and a clean one.

If it succeeds, Graves' is just a huge opportunity, and there is just so much patient need there.

Dennis Ding
Biotech Analyst, Jefferies

Do you think separation from placebo is all that you will need to succeed commercially?

Matt Gline
CEO, Roivant Sciences

I think the answer to that question is, on the primary endpoint, all we need to do is hit. There are a lot of things we are studying in this study, including things that look like our phase II endpoint, different versions of how much ATD titration there is.

You know, whether TSH is or is not a part of the calculus, whether there is remission or not. I think the overall clinical picture here is not about any specific endpoint. It is about showing across all of the endpoints that we are able to make a difference for these patients. I do not think I know there is some discussion out there, in addition to bolus, the other word that is a bad word for pharma CEOs is bar. There is some discussion out there about what good looks like in Graves' disease. My honest view is these are patients who have had no therapeutic options. If we are getting a significant number of uncontrolled thyroid patients to controlled T3 and T4, there is going to be a lot of demand for this product.

If we are getting a significant number of thyroid patients off ATDs or to low ATD doses, there is going to be a lot of demand for the product. I think mostly we need a successful study, and we need enough data across the portfolio of endpoints that we are studying,

to tell the narrative that we need to tell around our benefit for these patients. But I am not particularly worried about any specific endpoint.

Dennis Ding
Biotech Analyst, Jefferies

Okay. What about for MG and CIDP? How are you framing some of those readouts?

Matt Gline
CEO, Roivant Sciences

Yeah, so the MG pivotal data comes next year as well. That is, I mean, FcRn's work in MG, so I expect our FcRn will work in MG. MG is a commercially intense space at this point. I've said, and there's people who disagree with this claim. First of all, I think we have shown unambiguously across indica- RA, and talk about some RA data, but our 600 mg dose hit, and our 300 mg dose did basically nothing in RA.

That is just the next in a long string of evidence we have that deeper IgG suppression yields better clinical benefit for patients. There is a chance along those lines that our MG study will show either on MSE or some stringent, like effectively remission endpoint or otherwise, better efficacy than we have seen from other FcRn agents.

The honest answer from my perspective is if we ran a head-to-head study versus VYVGART tomorrow and trounced them-

it is still not obvious to me that we would win the majority of the share commercially because VYVGART has the brand, is an extremely well-loved drug, and it works pretty well for patients. That said, I think our drug should work in MG, and if it does, I think it should be commercially interesting, in part because MG is such a large market that even with a relatively smaller portion of class share, it's interesting. But I don't think of it as the pillar of IMVT-1402 strategy in the same way that I think of Graves' disease or D2T RA as really important for us as commercial markets. CIDP is probably somewhere in the middle. Obviously, argenx has established itself in CIDP pretty well, but I think there's more, quote-unquote, room for improvement there.

I think the FcRn so far have shown good, but not spectacular sort of clean-it-up data.

And I think you hear that a little bit from argenx as they now talk about combos with complement pathway stuff and CIDP and so on. So I think there is more room for improvement. The other thing that is going to make CIDP interesting is FDA's stance on trial design has changed, so our trial and all the other current generation of trials are more vanilla head-to-head versus placebo random trials.

Whereas the first generation of studies were generally randomized withdrawal studies.

Dennis Ding
Biotech Analyst, Jefferies

Yeah.

Matt Gline
CEO, Roivant Sciences

I think that will have some impact. We have gotten better at patient selection in CIDP generally in a way that I think will win the day, but I do think that will be a dynamic to watch. But anyway, I think CIDP is a big opportunity for us if our data is compelling.

Dennis Ding
Biotech Analyst, Jefferies

Okay. We have one and a half minutes left, and I really wish we had another 10 minutes to talk about PH-ILD because of the phase II data that you guys showed was really, really impressive. So maybe just remind us what you showed on PVR six-minute walk and then where you are in phase III.

Matt Gline
CEO, Roivant Sciences

Can I talk for nine minutes? No, look, pulmonary hypertension, first of all, obviously as investors, people are accustomed to pulmonary hypertension as an investable indication because people have been treating it for a long time. United Therapeutics, Acceleron, it will come to me. Anyway, a lot of companies have been in pulmonary hypertension, Actelion. It is a bad disease, right? PH-ILD, which is sort of where PAH was 15 years ago, two to three year mortality. It is just a really bad disease where every option is needed. We were hoping for a reasonable, call it 20%+ benefit on PVR, and we were hoping for some separation on six-minute walk, but maybe not a P-value.

We got 50-something percent placebo-adjusted separation on PVR, and we got 35 m of placebo-adjusted separation on six-minute walk with a nice P-value, and that got bigger over time as you got to week 24. This was just incredible data that will matter to patients. We also, one of the problems with TYVASO, which inhaled treprostinil, is it causes cough as an on-target effect, and we had less cough than placebo in our study. I think, in short, mosliciguat has the potential to be a big drug in a lot of indications for us, and we are, as with the others, really going broad now.

Dennis Ding
Biotech Analyst, Jefferies

Okay. Lastly, real quick, just the treprostinil combo study, when do you think we will get that?

Matt Gline
CEO, Roivant Sciences

It is an open-label study. It is ongoing now. We should have a decent number of patients in into next year, and so we will share data when we are ready.

Dennis Ding
Biotech Analyst, Jefferies

Okay, perfect.

Matt Gline
CEO, Roivant Sciences

Awesome.

Dennis Ding
Biotech Analyst, Jefferies

Well, thanks so much, Matt.

Matt Gline
CEO, Roivant Sciences

Thanks so much.

Dennis Ding
Biotech Analyst, Jefferies

Yep.

Matt Gline
CEO, Roivant Sciences

Thanks, everybody.